Celularity (NASDAQ:CELU) Trading Up 2.4% – Here’s What Happened

Celularity, Inc. (NASDAQ:CELU – Get Free Report)’s stock price shot up 2.4% during mid-day trading on Wednesday . The stock traded as high as $0.8468 and last traded at $0.8252. 275,318 shares were traded during trading, an increase of 51% from the average session volume of 182,465 shares. The stock had previously closed at $0.8061.

Celularity Stock Up 2.4%

The stock has a market capitalization of $23.89 million, a price-to-earnings ratio of -0.25 and a beta of 0.44. The company’s 50-day simple moving average is $1.14 and its 200 day simple moving average is $1.34.

Get Celularity alerts:

Celularity (NASDAQ:CELU – Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($0.85) EPS for the quarter. The business had revenue of $4.10 million for the quarter.

Hedge Funds Weigh In On Celularity

Several hedge funds have recently bought and sold shares of CELU. Acadian Asset Management LLC acquired a new position in Celularity during the first quarter worth $34,000. XTX Topco Ltd increased its position in Celularity by 106.4% during the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock worth $42,000 after buying an additional 11,057 shares during the last quarter. Bank of America Corp DE increased its position in Celularity by 1,538.1% during the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after buying an additional 35,023 shares during the last quarter. Vanguard Group Inc. increased its position in Celularity by 35.3% during the third quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock worth $1,401,000 after buying an additional 176,518 shares during the last quarter. Finally, Perennial Investment Advisors LLC acquired a new position in Celularity during the third quarter worth $28,000. 19.02% of the stock is owned by institutional investors and hedge funds.

About Celularity

(Get Free Report)

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.

Further Reading

• Five stocks we like better than Celularity
• From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
• AI Consolidation Begins: Blackstone & Google Forge an AI Empire
• USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
• 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO

Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.